Royalty Pharma PLC
NASDAQ:RPRX

Watchlist Manager
Royalty Pharma PLC Logo
Royalty Pharma PLC
NASDAQ:RPRX
Watchlist
Price: 38.685 USD 0.38%
Market Cap: 22.6B USD
Section:
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one RPRX stock under the Base Case scenario is 57.535 USD. Compared to the current market price of 38.685 USD, Royalty Pharma PLC is Undervalued by 33%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

RPRX Relative Value
Base Case
57.535 USD
Undervaluation 33%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

9.5
P/S
P/S
Price to Sales
9.5
vs History
0
vs Industry
16
Median 3Y
7
Median 5Y
7.1
Industry
2.6
Forward
7.2
More Details
29.2
P/E
P/E
Price to Earnings
29.2
vs History
33
vs Industry
21
Median 3Y
24.8
Median 5Y
25.8
Industry
21.8
Forward
8.4
More Details
9.3
P/OCF
P/OCF
Price to OCF
9.3
vs History
0
vs Industry
43
Median 3Y
5.9
Median 5Y
7.2
Industry
16.5
More Details
10.3
P/FCFE
P/FCFE
Price to FCFE
10.3
vs History
80
vs Industry
29
Median 3Y
19.9
Median 5Y
19.9
Industry
22.8
More Details
3.5
P/B
P/B
Price to Book Value
3.5
vs History
3
vs Industry
26
Median 3Y
2.6
Median 5Y
2.7
Industry
2.3
More Details
12.4
EV/S
EV/S
Enterprise Value to Sales
12.4
vs History
0
vs Industry
12
Median 3Y
9.1
Median 5Y
8.9
Industry
2.8
Forward
9.4
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5.4
More Details
19
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
19
vs History
34
vs Industry
19
Median 3Y
19
Median 5Y
14.8
Industry
12.7
Forward
10
More Details
19
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
19
vs History
34
vs Industry
23
Median 3Y
19
Median 5Y
14.8
Industry
16.3
Forward
10.6
More Details
12.1
EV/OCF
EV/OCF
Enterprise Value to OCF
12.1
vs History
0
vs Industry
41
Median 3Y
7.7
Median 5Y
8.9
Industry
15.1
More Details
30.8
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
30.8
vs History
52
vs Industry
5
Median 3Y
37.2
Median 5Y
31.5
Industry
17.7
More Details
1.7
EV/IC
EV/IC
Enterprise Value to IC
1.7
vs History
0
vs Industry
43
Median 3Y
1.3
Median 5Y
1.4
Industry
2
More Details

Multiples Across Competitors

RPRX Competitors Multiples
Royalty Pharma PLC Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Royalty Pharma PLC
NASDAQ:RPRX
22.3B USD 9.5 29.2 19 19
US
Eli Lilly and Co
NYSE:LLY
920.3B USD 15.6 50.2 33.6 36
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
456.1B USD 4.9 18.2 14.9 19.4
CH
Roche Holding AG
SIX:ROG
226.8B CHF 3.7 24.1 10.9 12.4
UK
AstraZeneca PLC
LSE:AZN
208B GBP 4.7 29.1 108.1 158.2
CH
Novartis AG
SIX:NOVN
197.9B CHF 4.4 17.1 10.9 14
US
Merck & Co Inc
NYSE:MRK
215.8B USD 3.4 11.3 8.2 9.7
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.3 13.1 9.2 10.7
IE
Endo International PLC
LSE:0Y5F
202B USD 87.1 -69.1 320.4 803.4
US
Pfizer Inc
NYSE:PFE
140B USD 2.2 14.3 7.3 10
P/E Multiple
Earnings Growth PEG
US
Royalty Pharma PLC
NASDAQ:RPRX
Average P/E: 22.9
29.2
57%
0.5
US
Eli Lilly and Co
NYSE:LLY
50.2
50%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
18.2
29%
0.6
CH
Roche Holding AG
SIX:ROG
24.1
29%
0.8
UK
AstraZeneca PLC
LSE:AZN
29.1
38%
0.8
CH
Novartis AG
SIX:NOVN
17.1
18%
0.9
US
Merck & Co Inc
NYSE:MRK
11.3
15%
0.8
DK
Novo Nordisk A/S
CSE:NOVO B
13.1
7%
1.9
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -69.1 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.3
31%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Royalty Pharma PLC
NASDAQ:RPRX
Average EV/EBITDA: 399
19
38%
0.5
US
Eli Lilly and Co
NYSE:LLY
33.6
30%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
14.9
8%
1.9
CH
Roche Holding AG
SIX:ROG
10.9
5%
2.2
UK
AstraZeneca PLC
LSE:AZN
108.1
10%
10.8
CH
Novartis AG
SIX:NOVN
10.9
6%
1.8
US
Merck & Co Inc
NYSE:MRK
8.2
7%
1.2
DK
Novo Nordisk A/S
CSE:NOVO B
9.2
6%
1.5
IE
E
Endo International PLC
LSE:0Y5F
320.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.3
1%
7.3
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Royalty Pharma PLC
NASDAQ:RPRX
Average EV/EBIT: 1 708.6
19
31%
0.6
US
Eli Lilly and Co
NYSE:LLY
36
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
19.4
14%
1.4
CH
Roche Holding AG
SIX:ROG
12.4
6%
2.1
UK
AstraZeneca PLC
LSE:AZN
158.2
22%
7.2
CH
Novartis AG
SIX:NOVN
14
12%
1.2
US
Merck & Co Inc
NYSE:MRK
9.7
9%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
10.7
6%
1.8
IE
E
Endo International PLC
LSE:0Y5F
803.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10
10%
1

See Also

Summary
RPRX intrinsic value, competitors valuation, and company profile.
DCF Valuation
RPRX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
RPRX stock valuation using valuation multiples.
Wall Street Estimates
RPRX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
RPRX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 295,700+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.